NGM Biopharmaceuticals, Inc.
NGMNASDAQHealthcare
$1.54
$-0.02(-1.28%)
Market Cap$128532096
P/E Ratio—
52W High$4.69
52W Low$0.6002
NGM Biopharmaceuticals, Inc. (NGM) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · NGM · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2023-12 | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $4.42M | $55.33M | $77.88M | $87.37M | $103.54M |
| Cost of Revenue | $2.22M | $5.98M | $7.90M | $163.97M | $129.25M |
| Gross Profit | $2.20M | $49.35M | $69.98M | ($76.60M) | ($25.71M) |
| Gross Margin %(computed) | 49.72% | 89.19% | 89.86% | -87.68% | -24.83% |
| Operating Expenses | |||||
| R&D Expenses | $112.01M | $181.07M | $161.71M | $163.97M | $129.25M |
| G&A Expenses | $37.84M | $40.52M | $36.87M | $27.23M | $23.63M |
| Total Operating Expenses | $148.74M | $221.58M | $198.58M | $191.20M | $152.88M |
| Operating Income | ($146.55M) | ($166.25M) | ($120.69M) | ($103.83M) | ($49.34M) |
| Operating Margin %(computed) | — | -300.45% | -154.97% | -118.85% | -47.65% |
| Interest Income | $9.32M | $3.71M | $0.42M | $1.94M | $6.69M |
| Interest Expense | $0.00M | $3.71M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($142.38M) | ($162.67M) | ($120.33M) | ($102.49M) | ($42.80M) |
| Income Tax Expense | $0.00M | ($3.58M) | ($6.51M) | ($8.49M) | ($14.30M) |
| Net Income | ($142.38M) | ($159.09M) | ($113.83M) | ($93.99M) | ($28.50M) |
| Net Margin %(computed) | — | -287.50% | -146.15% | -107.58% | -27.52% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.73 | $-1.99 | $-1.48 | $-1.37 | $-0.57 |
| Wtd Avg Shares | 82.50M | 79.95M | 77.09M | 68.48M | 50.30M |
| EBITDA | ($144.33M) | ($154.92M) | ($120.69M) | ($103.83M) | ($49.34M) |
| EBITDA Margin %(computed) | — | -279.97% | -154.97% | -118.85% | -47.65% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more NGM Biopharmaceuticals, Inc. data
About NGM Biopharmaceuticals, Inc. (NGM) Income Statement
NGM Biopharmaceuticals, Inc. (NGM) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2023, NGM reported revenue of $0.00B, gross profit of $0.00B (gross margin 49.72%), and net income of ($0.14B) — a net profit margin of -3223.34%.
Frequently asked questions
NGM · 4 questionsNGM Biopharmaceuticals, Inc. (NGM) reported revenue of $0.00B for 2023, down 92.0% year-over-year.
NGM revenueNGM salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09